Therefore, the STAT1-PD-L1-NFATc1 pathway was proposed to reveal the immunosuppressive mechanism of PD-L1, which may increase the potential for PD-L1-based antitumor immunotherapy for bladder cancer [43]. This evidence concerns the gene STAT1 and urinary bladder carcinoma.